Results 181 to 190 of about 235,541 (221)
Some of the next articles are maybe not open access.
PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX)
Retina, 2020Purpose: To describe persistent remnants of dexamethasone intravitreal implant (DEX implant) and evaluate the risk factors for remnant persistence in patients who received a DEX implant. Methods: This retrospective observational study involved a retrospective chart review of 133 ...
Jee Taek, Kim +2 more
openaire +2 more sources
An update on intravitreal implants in use for eye disorders
Drugs of Today, 2014Advanced biotechnological techniques and new polymers have led to the development of many innovative intravitreal drug delivery systems. Some designs are still in an experimental phase while others have gained widespread acceptance and are commercially available.
LAMBIASE, ALESSANDRO +2 more
openaire +3 more sources
Corticosteroid Intravitreal Implants
2012Intraocular implants developed for ocular inflammation which release glucocorticoids for a prolonged period within the vitreous cavity make use of either a bioerodible polymer (dexamethasone in polylactic acid-coglycolic acid matrix) or non-erodible implantable device (fluocinolone acetonide, FA, in a polyvinyl acetate/silicone laminate ...
openaire +2 more sources
Intravitreal dexamethasone implants for non‐infectious uveitis
Clinical & Experimental Ophthalmology, 2019AbstractImportanceInflammatory‐mediated cystoid macular oedema (CMO) is the most common inflammatory‐mediated threat to vision in non‐infectious uveitis (NIU). Corticosteroid therapy is the cornerstone to the management of CMO in NIU. Sustained‐release dexamethasone (DEX) implant devices provide localized therapy.BackgroundThe authors present a series ...
Matthew McCartney +2 more
openaire +2 more sources
MIGRATION OF INTRAVITREAL DEXAMETHASONE IMPLANT TO ANTERIOR CHAMBER
RETINAL Cases & Brief Reports, 2013Purpose: To describe two cases of migration of intravitreally injected dexamethasone implant into the anterior chamber. Methods: Charts were reviewed of two patients who received sustained-release dexamethasone implant intravitreally for chronic intractable cystoid macular edema.
Vamsi K, Gullapalli, David A, DiLoreto
openaire +2 more sources
Pharmacologic and clinical profile of dexamethasone intravitreal implant
Expert Review of Clinical Pharmacology, 2012The challenge in the treatment of chronic retinal diseases is to deliver effective therapy to the target tissues in the back of the eye while limiting drug exposure in nontarget tissues. Intravitreal placement provides the most targeted drug delivery, but repeated penetration of the globe to deliver intravitreal therapy can pose safety risks.
Michael R, Robinson, Scott M, Whitcup
openaire +2 more sources
Dexamethasone: intravitreal implant.
Prescrire international, 2011Macular oedema is one of the complications of retinal vein occlusion. About half of the patients recover spontaneously within 3 to 6 months. There is currently no drug that improves outcome. An intravitreal implant delivering 0.7 mg of dexamethasone has been authorised for the treatment of macular oedema in this setting. Clinical assessment is based on
openaire +1 more source
Current Eye Research, 2015
To evaluate the safety and efficacy of intravitreal dexamethasone implant (Ozurdex) in patients with chronic diabetic macular edema (DME) resistant to prior intravitreal bevacizumab (IVB) treatment.Thirty eyes of 30 patients were administered intravitreal Ozurdex and examined at baseline and 1, 3, and 6 months postinjection in this prospective study ...
Totan, Yuksel +2 more
openaire +3 more sources
To evaluate the safety and efficacy of intravitreal dexamethasone implant (Ozurdex) in patients with chronic diabetic macular edema (DME) resistant to prior intravitreal bevacizumab (IVB) treatment.Thirty eyes of 30 patients were administered intravitreal Ozurdex and examined at baseline and 1, 3, and 6 months postinjection in this prospective study ...
Totan, Yuksel +2 more
openaire +3 more sources
Cyclodialysis Complicating Intravitreal Ganciclovir Implantation
Archives of Ophthalmology, 1997Intravitreal ganciclovir implantation is an effective treatment for cytomegalovirus retinitis. An implant recently has been approved by the Food and Drug Administration and is commercially available. Because implantation eliminates the need for an indwelling catheter and offers an improved quality of life, it may become a more popular initial treatment
openaire +1 more source
Re: Intravitreal dexamethasone implant fragmentation
Canadian Journal of Ophthalmology, 2013Javier, Cabrerizo +1 more
openaire +2 more sources